Current Therapeutic Uses,Pharmacology,and Clinical Considerations of Neuromuscular Blocking Agents for Critically III Adults

Abstract

Spanish

French

Objective:

To summarize literature describing use of neuromuscular blocking agents (NMBAs) for common critical care indications and provide a review of NMBA pharmacology, pharmacokinetics, dosing, drug interactions, monitoring, complications, and reversal.

Data Sources:

Searches of MEDLINE (1975-May 2011). EMBASE (1960-May 2011), and Cumulative Index to Nursing and Allied Health Literature (1981-May 2011) were conducted to identify observational and interventional studies evaluating the efficacy or safety of NMBAs for management of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), status asthmaticus, elevated intracranial pressure (ICP), and therapeutic hypothermia.

Study Selection And Data Extraction:

We excluded case reports, animal- or laboratory-based studies, trials describing NMBA use during rapid sequence intubation or in the operating room, and studies published in languages other than English or French.

Data Synthesis:

Clinical applications of NMBAs in intensive care include, but are not limited to, immobilizing patients for procedural interventions, decreasing oxygen consumption, facilitating mechanical ventilation, reducing intracranial pressure, preventing shivering, and management of tetanus. Recent data on ARDS demonstrated that early application of NMBAs improved adjusted 90-day survival for patients with severe lung injury. These results may lead to increased use of these drugs. While emerging data support the use of cisatracurium in select patients with ALI/ARDS, current literature does not support the use of one NMBA over another for other critical care indications. Cisatracurium may be kinetically preferred for patients with organ dysfunction. Close monitoring with peripheral nerve stimulation is recommended with sustained use of NMBAs to avoid drug accumulation and minimize the risk for adverse drug events. Reversal of paralysis is achieved by discontinuing therapy or, rarely, the use of anticholinesterases.

Conclusions:

NMBAS are high-alert medications used to manage critically ill patients. New data are available regarding the use of these agents for treatment of ALI/ARDS and status asthmaticus, management of elevated ICP, and provision of therapeutic hypothermia after cardiac arrest. To improve outcomes and promote patient safety, intensive care unit team members should have a thorough knowledge of this class of medications.

Keywords

chemical paralysis critical care intensive care mechanical ventilation neuromuscular blockade

Get full access to this article

View all access options for this article.

References

Arroliga

, Frutos-Vivar

, Hall

. Use of sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. Chest 2005; 128:496–506.

Murray

, Cowen

, DeBlock

. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med 2002; 30:142–56.

Vender

, Szokol

, Murphy

, Nitsun

. Sedation, analgesia, and neuromuscular blockade in sepsis: an evidence-based review. Crit Care Med 2004; 32:S554–61.

The Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002; 346:549–56.

Bernard

, Gray

, Buist

. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002; 346:557–63.

Raoof

, Goulet

, Esan

. Severe hypoxemic respiratory failure. Part 2- nonventilatory strategies. Chest 2010; 137:1437–48.

The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342:1301–8.

Arroliga

, Thompson

, Ancukiewicz

. Use of sedatives, opioids, and neuromuscular blocking agents in patients with acute lung injury and acute respiratory distress syndrome. Crit Care Med 2008; 36:1083–8.

Meade

, Cook

, Guyatt

. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2008; 299:637–45.

10.

Mercat

, Richard

, Vielle

. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized-controlled trial. JAMA 2008; 229:646–55.

11.

Sessler

. Sedation, analgesia and neuromuscular blockade for high-frequency oscillatory ventilation. Crit Care Med 2005; 33:S209–16.

12.

Mehta

, MacDonald

, Bowman

. High frequency oscillatory ventilation (HFOV) in adults: the Toronto experience. Chest 2004; 126:518–27.

13.

Taccone

, Pesenti

, Latini

. Prone positioning in patients with moderate and severe acute respiratory distress syndrome: a randomized controlled trial. JAMA 2009; 302:1977–84.

14.

Kumar

, Zarychanski

, Pinto

. Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA 2009; 302:1872–9.

15.

Papazian

, Forel

, Gacouin

. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010; 363:1107–16.

16.

Bishop

. Hemodynamic and gas exchange effects of pancuronium bromide in sedated patients with respiratory failure. Anesthesiology 1984; 60:369–71.

17.

Conti

, Vilardi

, Rocco

. Paralysis has no effect on chest wall and respiratory system mechanics of mechanically ventilated, sedated patients. Intensive Care Med 1995; 21:808–12.

18.

Lagneau

, D'Honneur

, Plaud

. A comparison of two depths of prolonged neuromuscular blockade induced by cisatracurium in mechanically ventilated critically ill patients. Intensive Care Med 2002; 28:1735–41.

19.

Gainnier

, Roch

, Forel

. Effect of neuromuscular blocking agents on gas exchange in patients presenting with ARDS. Crit Care Med 2004: 32:113–9.

20.

Forel

, Roch

, Marin

. Neuromuscular blocking agents decrease inflammatory response in patients presenting with ARDS. Crit Care Med 2006; 34:2749–57.

21.

Leatherman

, Fluegel

, David

. Muscle weakness in mechanically ventilated patients with severe asthma. Am J Respir Crit Care Med 1996; 153:1686–90.

22.

Behbehani

, Al-Mane

, D'yachkova

. Myopathy following mechanical ventilation for severe acute asthma: the role of muscle relaxants and corticosteroids. Chest 1999; 115:1627–31.

23.

Adnet

, Dhissi

, Borron

. Complication profiles of adult asthmatics requiring paralysis during mechanical ventilation. Intensive Care Med 2001; 27:1729–36.

24.

Kesler

, Sprenkle

, David

. Severe weakness complicating status asthmaticus despite minimal duration of neuromuscular paralysis. Intensive Care Med 2009; 35:157–60.

25.

Hsiang

, Chestnut

, Crisp

. Early, routine paralysis for intracranial pressure control in severe head injury: is it necessary? Crit Care Med 1994; 22:1471–6.

26.

Schramm

, Jesenko

, Bartunek

. Effects of cisatracurium on cerebral and cardiovascular hemodynamics in patients with severe brain injury. Acta Anaesthesiol Scand 1997; 41:1319–23

27.

Prielipp

, Robinson

, Wilson

. Dose response, recovery and cost of doxacurium as a continuous infusion in neurosurgical intensive care unit patients. Crit Care Med 1997; 25:1236–41.

28.

Schramm

, Papousek

, Michalek-Sauberer

. The cerebral and cardiovascular effects of cisatracurium and atracurium in neurosurgical patients. Anesth Analg 1998; 86:123–7.

29.

Kerr

, Sereika

, Orndoff

. Effect of neuromuscular blockers and opiates on the cerebrovascular response to endotracheal suctioning in adults with severe head injuries. Am J Crit Care 1998; 7:205–17.

30.

Juul

, Morris

, Marshall

. Neuromuscular blocking agents in neurointensive care. Acta Neurochir Suppl 2000; 76:467–70.

31.

Brunton

, Lazo

, Parker

. Agents acting at the neuromuscular junction and autonomic ganglia. In: Shanahan

, Foltin

, Edmonson

, Brown

eds. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2007: 217–36.

32.

Irwin

, Rippe

. Therapeutic paralysis. In: Irwin

, Rippe

eds. Irwin and Rippe's intensive care medicine. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2008: 224–30.

33.

McManus

. Neuromuscular blockers in surgery and intensive care, part 2. Am J Health Syst Pharm 2001; 58:2381–95.

34.

El-Orbany

, Connolly

. Rapid sequence induction and intubation: current controversy. Anesth Analg 2010; 110:1318–25.

35.

Brunton

, Goodman

, Blumenthal

, Buxton

. Sequence and characteristics of paralysis. In: Goodman and Gilman's manual of pharmacology and therapeutics. 11th ed. New York: McGraw-Hill, 2007: 136.

36.

Catineau

, Porte

, d'Honneur

, Duvaldestin

. Neuromuscular effects of rocuronium on the diaphragm and adductor pollicis muscles in anaesthetized patients. Anesthesiology 1994; 81:585–90.

37.

Forel

, Roch

, Papazian

. Paralytics in critical care: not always the bad guy. Curr Opin Crit Care 2009; 15:59–66.

38.

Papiris

, Manali

, Kolilekas

. Acute severe asthma: new approaches to assessment and treatment. Drugs 2009; 69:2363–91.

39.

Rangel-Castillo

, Gopinath

, Robertson

. Management of intracranial hypertension. Neurol Clin 2008; 26:521–41.

40.

Brain Trauma Foundation, American Association of Neurological Surgeons (AANS), Congress of Neurological Surgeons (CNS), AANS/CNS Joint Section on Neurotrauma and Critical Care. Guidelines for the management of traumatic brain injury. J Neurotrauma 2007; 24:(suppl 1):S71–6.

41.

McClelland

, Woster

, Sweasey

. Continuous midazolam-atracurium infusions for the management of increased intracranial pressure. J Neurosa Nurs 1995; 27:96–101.

42.

Nolan

, Morley

, Vanden Hoek

. International Liaison Committee on Resuscitation. Therapeutic hypothermia after cardiac arrest: an advisory statement by the advanced life support task force of the International Liaison Committee on Resuscitation. Circulation 2003; 108:118–21.

43.

Soreide

, Sunke

. Therapeutic hypothermia after out-of-hospital cardiac arrest: how to secure worldwide implementation. Curr Opin Anaesthesiol 2008; 21:209–15.

44.

Nolan

, Neumar

, Adrie

. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment and prognostication. A Scientific Statement from the International Liaison Committee on Resuscitation. Resuscitation 2008; 79:350–79.

45.

Chamorro

, Borrallo

, Romera

. Anesthesia and analgesia protocol during therapeutic hypothermia after cardiac arrest: a systematic review. Anesth Analg 2010; 110:1328–35.

46.

Tortorici

, Kochanek

, Poloyac

. Effects of hypothermia on drug disposition, metabolism and response: a focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system. Crit Care Med 2007; 35:2196–204.

47.

Arpino

, Greer

. Practical pharmacologic aspects of therapeutic hypothermia after cardiac arrest. Pharmacotherapy 2008; 28:102–11.

48.

Van den Broeck

MPH

, Groenendaal

, Egberts

ACG

. Effects of hypothermia on pharmacokinetics and pharmacodynamics. A systematic review of preclinical and clinical studies. Clin Pharmacokinet 2010; 49:277–94.

49.

Heier

, Caldwell

. Impact of hypothermia on the response to neuromuscular blocking drugs. Anesthesiology 2006; 104:1070–80.

50.

Tatro

. Non-depolarizing muscle relaxants. In: Drug interaction facts. St. Louis, MO: Wolters Kluwer, 2010: 1231–53.

51.

Prielipp

, Coursin

. Applied pharmacology of common neuromuscular blocking agents in critical care. New Horiz 1994; 2:34–47.

52.

Nagler

, Krauss

. Capnographic monitoring in respiratory emergencies. Clin Pediatr Emerg Med 2009; 10:82–9.

53.

Loyola

, Dreher

. Management of pharmacologically induced neuromuscular blockade using peripheral nerve stimulation. Dimens Crit Care Nurs 2003; 22:157–64.

54.

Rudis

, Sikora

, Angus

. A prospective, randomized controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 1997; 25:575–93.

55.

Strange

, Vaughan

, Franklin

. Comparison of train-of-four and best clinical assessment during continuous paralysis. Am J Respir Crit Care Med 1997; 156:1556–61.

56.

Baumann

, McAlpin

, Brown

. A prospective randomized comparison of train-of-four monitoring and clinical assessment during continuous ICU cisatracurium paralysis. Chest 2004; 126:1267–73.

57.

Sorce

. Adverse responses: sedation, analgesia and neuromuscular blocking agents in critically ill children. Crit Care Nurs Clin North Am 2005; 17:441–50.

58.

Griffiths

, Hall

. Intensive care unit-acquired weakness. Crit Care Med 2010; 38:779–87.

59.

Srivastava

, Hunter

. Reversal of neuromuscular block. Br J Anaesth 2009; 103:115–29.

60.

Caldwell

. Clinical limitations of acetylcholinesterase antagonists. J Crit Care 2009; 24:21–8.